SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CRII - Cell Robotics International, Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: sheetmillgalvanize who wrote (228)12/29/1999 11:41:00 PM
From: fewbucks26  Read Replies (1) of 252
 
To All:

I need some help here. I came across CRII while doing some other research. Can someone give me the Reader's Digest version of why this stock is not much higher than it is? If the lasette is everything it's cracked up to be, it should address one of the key issues regarding patient compliance in managing diabetes, i.e. the fact that patients have to "prick their fingers" multiple times per day to test glucose levels. There is a significant need in the market place to provide a less painful solution.

So why isn't CRII much higher than $2-3?? If the lasette is such a hot product, why wouldn't Novo or Eli Lilly simply buy the company to gain the technology? It would compliment their insulin sales business. I know for a fact that these companies have paid for technologies that have tried to develop non-invasive means of testing glucose levels to try to improve patient compliance. There must be something I am missing. Who can fill me in?

A few other questions. What is the status regarding reimbursement, especially Medicare / Medicaid, but also private insurers? With a pricetag of $1,000 for the lasette, and the ongoing disposable cost for the "lens covers", I question how eager the insurance companies and government will be to cough up the money for a little less "pain and suffering". Without reimbursement, the market for this product will be dramatically reduced. Unfortunate, but true.

Second, what's the deal with the preferred stock that CRII has out? They have negative cashflow, and yet they are paying dividends on preferred stock. Not too nice to your (common) shareholders, CRII management!

It just doesn't make sense that this stock is at $2-3 if CRII has a breakthrough product for glucose testing. What's the missing link? Something's not right. Any info. would be appreciated.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News